by John Conrad | May 27, 2026 | iBIO in the News, Policy News
Yesterday in Springfield, iBIO President and CEO John Conrad testified on legislation that would expand and reshape how Illinois interacts with the federal 340B drug discount program—underscoring a principle iBIO believes must come first: independent, enforceable...
by John Conrad | May 12, 2025 | Policy News
“The President’s Most Favored Nation proposal represents a catastrophic misstep for American biosciences innovation and patient access to life-saving treatments,” said John Conrad, President and CEO of the Illinois Biotechnology Innovation Organization. “This...
by John Conrad | Oct 2, 2019 | Policy News
Policymakers in Washington are debating reforms they claim will lower prescription drug prices. It’s important our elected leaders offer real solutions instead of partisan soundbites that mask the real harm to patients by their government-run scheme. The House of...
by John Conrad | Jul 1, 2019 | 2019 Fed Issue
The HELP Committee advanced the Lower Health Care Costs Act of 2019 (S. 1895). While the bill deals with health care costs more broadly, it also contains provisions on drug pricing (such as the CREATES Act). The Committee adopted an amendment introduced by Senator...
by John Conrad | Jul 1, 2019 | 2019 Fed Issue
The Affordable Prescriptions for Patients Act (S. 1416), introduced by Senators John Cornyn (R-TX) and Richard Blumenthal (D-CT), was approved unanimously by the Judiciary Committee last week, as amended. As originally drafted, the bill would have granted the Federal...
